

Peter Nash

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3627080/peter-nash-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers

11,547
citations

46
h-index

106
g-index

175
ext. papers

13,598
ext. citations

5.8
avg, IF

5.76
L-index

#	Paper	IF	Citations
141	The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 11	5.7	1
140	Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry.. <i>Rheumatology and Therapy</i> , 2022 , 9, 735	4.4	0
139	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
138	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021 , 7,	5.9	1
137	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211057975	3.8	1
136	Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. <i>Rheumatology and Therapy</i> , 2021 , 8, 1827-1844	4.4	0
135	Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, 239-247	1.1	9
134	Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement'' by Banday. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
133	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e270-e283	14.2	7
132	Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. <i>RMD Open</i> , 2021 , 7,	5.9	9
131	Clinical use of Jak 1 inhibitors for rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, ii31-ii38	3.9	2
130	A comparison of Janus kinase inhibitor safety in rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 3-14	2.3	1
129	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
128	Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. <i>Lancet Rheumatology, The</i> , 2021 , 3, e28-e39	14.2	5
127	Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). <i>Rheumatology and Therapy</i> , 2021 , 8, 199-217	4.4	2
126	A patient-centered knowledge translation tool for treat-to-target strategy in rheumatoid arthritis: Patient and rheumatologist perspectives. <i>International Journal of Rheumatic Diseases</i> , 2021 , 24, 355-363	2.3	1
125	Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. <i>Arthritis Research and Therapy</i> , 2021 , 23, 41	5.7	5

124	Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program. <i>Drug Safety</i> , 2021 , 44, 515-530	5.1	13
123	The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C-Reactive Protein Levels. <i>ACR Open Rheumatology</i> , 2021 , 3, 699-706	3.5	1
122	Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	0
121	Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 848-858	2.4	32
120	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.. <i>Rheumatology and Therapy</i> , 2021 , 9, 521	4.4	5
119	Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib.. <i>Rheumatology and Therapy</i> , 2021 , 9, 411	4.4	0
118	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020 , 6,	5.9	36
117	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020 , 395, 1496-1505	4.0	83
116	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 553-580	4.4	29
115	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 709-718	5.3	8
114	Inhibition of interleukins 17A and 17F in psoriatic arthritis. <i>Lancet, The</i> , 2020 , 395, 395-396	4.0	8
113	A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 123-131	2.4	116
112	Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e227-e235	14.2	10
111	Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1210-1218	2.4	26
110	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , 2020 , 6,	5.9	12
109	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020 , 6,	5.9	10
108	Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. <i>Rheumatology and Therapy</i> , 2020 , 7, 1021-1033	4.4	4
107	Choosing the right treatment for patients with psoriatic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20962623	3.8	7

106	Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	13
105	256 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 4-year results from the Phase 3 FUTURE 2 study. <i>Rheumatology</i> , 2019 , 58,	3.9	3
104	257 Secukinumab demonstrates a consistent safety profile with up to 5 years of treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. <i>Rheumatology</i> , 2019 , 58,	3.9	1
103	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 878-891	9.5	38
102	Efficacy and Safety of Subcutaneous Secukinumab 150mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. <i>Rheumatology and Therapy</i> , 2019 , 6, 393-407	4.4	23
101	Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naïve patients with psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 497-510	2.1	11
100	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib. <i>RMD Open</i> , 2019 , 5, e000742	5.9	11
99	Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2019 , 6, 113-121	1.7	4
98	2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 357-375	2.3	60
97	FRI0457 SECUKINUMAB PROVIDES SIGNIFICANT AND SUSTAINED IMPROVEMENT IN NAIL PSORIASIS AND SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WITH NAIL PHENOTYPE: 52-WEEK RESULTS FROM THE PHASE III FUTURE 5 STUDY 2019 ,		3
96	LB0001 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH1 PRIMARY OUTCOME RESULTS 2019 ,		13
95	Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 367-378	4.7	36
94	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 566-574	2.2	5
93	Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 690-698	2.4	46
92	Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIB Trial. <i>Journal of Rheumatology</i> , 2018 , 45, 1085-1092	4.1	23
91	Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. <i>Clinical Rheumatology</i> , 2018 , 37, 1617-1623	3.9	8
90	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018 , 20, 47	5.7	69
89	Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. <i>Rheumatology and Therapy</i> , 2018 , 5, 99-122	4.4	31

88	Remission in psoriatic arthritis-where are we now?. <i>Rheumatology</i> , 2018 , 57, 1321-1331	3.9	8
87	Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. <i>Rheumatology</i> , 2018 , 57, 2001-2011	3.9	22
86	Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2018 , 5, 216-223	1.7	6
85	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
84	Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. <i>Journal of Rheumatology</i> , 2018 , 45, 177-187	4.1	13
83	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2018 , 5, 567-582	4.4	28
82	Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 272	5.7	20
81	Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 1107-1123	2.1	24
80	Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors. <i>RMD Open</i> , 2018 , 4, e000692	5.9	11
79	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018 , 20, 242	5.7	17
78	Psoriatic arthritis: novel targets add to a therapeutic renaissance. <i>Lancet, The</i> , 2018 , 391, 2187-2189	4.0	5
77	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. <i>Rheumatology and Therapy</i> , 2018 , 5, 383-401	4.4	8
76	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1253-1262	2.4	257
75	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-974	7.4	1649
74	Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study. <i>Advances in Therapy</i> , 2017 , 34, 1157-1172	4.1	14
73	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2317-2327	4.0	246
72	Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. <i>RMD Open</i> , 2017 , 3, e000465	5.9	7
71	Advances in rheumatoid arthritis. <i>Medical Journal of Australia</i> , 2017 , 206, 221-224	4	19

70	Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial. <i>Lupus Science and Medicine</i> , 2017 , 4, e000206	4.6	7
69	Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1293-301	2.4	47
68	Randomized Crossover Comparison of Injection Site Pain with 40mg/0.4 or 0.8mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2016 , 3, 257-270	4.4	48
67	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1060-71	9.5	485
66	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
65	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
64	Reply. <i>Arthritis Care and Research</i> , 2016 , 68, 1053-4	4.7	1
63	Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , 2016 , 68, 744-52	4.7	28
62	The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34 Suppl 100, 129-136	2.2	4
61	A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 7	5.7	63
60	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 1237-1245	4.7	67
59	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015 , 373, 1329-39	59.2	508
58	APLAR rheumatoid arthritis treatment recommendations. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 685-713	2.3	93
57	Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3234-44	9.5	58
56	Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S111-6	2.2	37
55	Updated guidelines for the management of axial disease in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2286-9	4.1	27
54	Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1987-97	9.5	42
53	An ImmunoChip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3. <i>Arthritis Research and Therapy</i> , 2014 , 16, 438	5.7	42

52	Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. <i>Journal of Rheumatology</i> , 2014 , 41, 629-39	4.1	27
51	Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 757-66	4.5	26
50	Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 918-29	4.0	266
49	Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study. <i>International Journal of Rheumatic Diseases</i> , 2013 , 16, 652-61	2.3	13
48	The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. <i>Arthritis Research and Therapy</i> , 2013 , 15, R193	5.7	37
47	Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 559-70		402
46	Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. <i>Rheumatology</i> , 2013 , 52, 155-60	3.9	122
45	Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. <i>Arthritis Care and Research</i> , 2013 , 65, 718-28	4.7	55
44	Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. <i>Arthritis Care and Research</i> , 2013 , 65, 1732-42	4.7	29
43	Treatment goals for moderate to severe psoriasis: an Australian consensus. <i>Australasian Journal of Dermatology</i> , 2013 , 54, 148-54	1.3	36
42	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 986-91	2.4	192
41	N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. <i>Arthritis Research and Therapy</i> , 2012 , 14, R143	5.7	65
40	Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. <i>Arthritis Research and Therapy</i> , 2011 , 13, R211	5.7	108
39	Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2854-64		144
38	Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. <i>Arthritis Research and Therapy</i> , 2011 , 13, 114	5.7	6
37	Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2011 , 38, 2419-27	4.1	2
36	Registries in systemic sclerosis: a worldwide experience. <i>Rheumatology</i> , 2011 , 50, 60-8	3.9	31
35	Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1360-3	2.4	27

34	Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. <i>Journal of Rheumatology</i> , 2010 , 37, 1885-91	4.1	31
33	Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. <i>Journal of Rheumatology</i> , 2010 , 37, 1488-501	4.1	126
32	Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group. <i>Journal of Rheumatology</i> , 2010 , 37, 105-15	4.1	29
31	Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study. <i>Clinical Therapeutics</i> , 2010 , 32, 1329-42	3.5	10
30	The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3077-87		270
29	Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2010 , 28, S47-52	2.2	6
28	The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1377-80	2.4	113
27	Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009 , 36, 2356-61	4.1	32
26	Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. <i>Rheumatology</i> , 2009 , 48 Suppl 3, iii25-31	3.9	48
25	Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 51, 3373-82		334
24	Assessment and treatment of psoriatic spondylitis. <i>Current Rheumatology Reports</i> , 2009 , 11, 278-83	4.9	3
23	Treatment recommendations for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1387-94	2.4	386
22	The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. <i>International Journal of Rheumatic Diseases</i> , 2009 , 12, 192-206	2.3	15
21	The complexity of managing systemic sclerosis: screening and diagnosis. <i>Rheumatology</i> , 2009 , 48 Suppl 3, iii8-13	3.9	22
20	Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. <i>Arthritis and Rheumatism</i> , 2008 , 58, 964-75		212
19	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 867-75		45
18	Initiative for quality in psoriasis and psoriatic arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 1431-3	4.1	1
17	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 1167-70	4.1	144

16	Alefacept plus methotrexate for psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 470-1		5
15	Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. <i>Dermatology</i> , 2006 , 212, 238-49	4.4	47
14	Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. <i>Lancet, The</i> , 2006 , 368, 855-63	4.0	145
13	Anti-tumor necrosis factor therapy: the Australian experience. <i>APLAR Journal of Rheumatology</i> , 2006 , 9, 119-123		2
12	Therapies for axial disease in psoriatic arthritis. A systematic review. <i>Journal of Rheumatology</i> , 2006 , 33, 1431-4	4.1	25
11	Seronegative spondyloarthropathies: to lump or split?. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii9-13	2.4	32
10	Psoriatic arthritis: epidemiology, clinical features, course, and outcome. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii14-7	2.4	619
9	OMERACT 7 psoriatic arthritis workshop: synopsis. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii115-6	2.4	16
8	Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 2, ii74-7	2.4	54
7	Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1460-9	2.4	130
6	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004 , 50, 24-35		151
5	Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1939-50		298
4	Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 508-16	2.4	440
3	Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 919-24	6.3	101
2	Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 913-23	2.4	108
1	Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. <i>Archives of Internal Medicine</i> , 2000 , 160, 2917-22		97